# M18-803 T-PLL

## Inclusion criteria

http://www.hovon.nl/template/images/bg-dot.gif Adequate liver, kidney and hematology function per laboratory values as described in the protocol.  
http://www.hovon.nl/template/images/bg-dot.gif Diagnosis of T-cell prolymphocytic leukemia (T-PLL) that requires treatment.  
http://www.hovon.nl/template/images/bg-dot.gif Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.  
http://www.hovon.nl/template/images/bg-dot.gif Negative for human T-cell lymphotropic virus, type 1.  
http://www.hovon.nl/template/images/bg-dot.gif Received prior alemtuzumab (unless unsuitable or unavailable).  
http://www.hovon.nl/template/images/bg-dot.gif Has no malignancies other than T-PLL that:  
o Currently require systemic therapies;  
o Were not previously treated with curative intention (unless the malignant disease is in a stable remission due to the discretion of the treating physician); or  
o Developed signs of progression after curative treatment

## Exclusion criteria

http://www.hovon.nl/template/images/bg-dot.gif History of or current decompensated cirrhosis including Child-Pugh class B or C, ascites, hepatic encephalopathy, or variceal bleeding.  
http://www.hovon.nl/template/images/bg-dot.gif Has human T-cell lymphotropic virus, type 1.  
http://www.hovon.nl/template/images/bg-dot.gif Prior allogeneic stem cell transplant within 6 months of study drug administration and requirement for graft versus host therapy.  
http://www.hovon.nl/template/images/bg-dot.gif Has an uncontrolled or active infection.  
http://www.hovon.nl/template/images/bg-dot.gif Previously treated with a B-cell lymphoma (BCL)-2 inhibitor.  
http://www.hovon.nl/template/images/bg-dot.gif Received a prohibited therapy within the specified time frame as described in the protocol.